WHY IS IT MOVING? · 2026-11-18 00:09 UTC
Why is INJ up 8.1% today?
+8.1 %
24 hours
$7.44
Price then
$134.0M
Traded, 24 h
+0.3 %
Bitcoin, same 24 h
What the news sayswritten from the headlines below
INJ rose 8.1% over the past 24 hours while Bitcoin moved very little, pointing to its own distinct price action [2]. The token gained ground alongside reports of growing tokenized assets, regulatory recognition, and new partnerships [2, 3, 6].
- Injective crossed $1 billion in tokenized assets alongside growth in its regulated toolkit [2]. [2]
- The project gained recognition from the CFTC as price outlook reports pointed to a potential breakout [3]. [3]
- An altcoin rally and positive news contributed to the asset rebounding 8 to 9 percent [4]. [4]
- Injective rallied following a Tokyo partnership and SEC transfer-agent news [6]. [6]
Market data also shows a squeeze of short sellers where over $730,000 in short positions were liquidated, though the exact timing and trigger of those liquidations are not fully detailed in the news.
The facts we measured
- INJ is up 8.1 % over 24 hours on Binance futures, with $134 million traded.
- Bitcoin is +0.3 % in the same 24 hours — INJ moved on its own, not with the market.
- Futures traders were forced out on INJ: $239,361 of longs and $733,510 of shorts liquidated in 24 hours — mostly shorts, the mark of a short squeeze.
The day's headlines
From the news in the 24 hours before this page was written — the numbers the write-up cites.
- ZachXBT accuses CoinJoin operator Kruw of laundering funds for Lazarus Group — Crypto Briefing, 2026-11-17 19:53 UTC
- Injective crosses $1 billion in tokenized assets as its regulated toolkit grows — Crypto Briefing, 2026-11-17 19:35 UTC
- Injective Gains CFTC Recognition As INJ Price Outlook Points To Potential Breakout — TronWeekly, 2026-11-17 19:18 UTC
- Injective (INJ) Rebounds 8-9% Amid Altcoin Rally and Positive News — CoinMarketCap, 2026-11-17 16:05 UTC
Other moves
What moved a price is rarely certain: this page says what the headlines and the numbers show, not what comes next. Research and education, not investment advice.